首页> 美国卫生研究院文献>BMC Pulmonary Medicine >External validation of multidimensional prognostic indices (ADO BODEx and DOSE) in a primary care international cohort (PROEPOC/COPD cohort)
【2h】

External validation of multidimensional prognostic indices (ADO BODEx and DOSE) in a primary care international cohort (PROEPOC/COPD cohort)

机译:在国际基层医疗队列(PROEPOC / COPD队列)中对多维预后指标(ADOBODEx和DOSE)进行外部验证

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundDue to the heterogeneous and systemic nature of the chronic obstructive pulmonary disease (COPD), the new guidelines are oriented toward individualized attention. Multidimensional scales could facilitate its proper clinical and prognostic assessment, but not all of them were validated in an international primary care cohort, different from the original ones used for model development. Therefore, our main aim is to assess the prognostic capacity of the ADO, BODEx and DOSE indices in primary care for predicting mortality in COPD patients and to validate the models obtained in subgroups of patients, classified by revised Global Initiative for Chronic Obstructive Lung Disease (2011) and updated Spanish Guideline (2014). Besides, we want to confirm that the prognostic capacity of all indices increases if the number of exacerbations is substituted by the interval between them and to assess the impact on health of the patient’s lifestyle, social network and adherence to treatment.
机译:背景由于慢性阻塞性肺疾病(COPD)的异质性和系统性,新指南针对的是个体化关注。多维量表可以促进其正确的临床和预后评估,但并不是所有的量表都在国际初级保健队列中得到了验证,这与用于模型开发的原始量表不同。因此,我们的主要目的是评估ADO,BODEx和DOSE指数在初级保健中的预测预后的能力,以预测COPD患者的死亡率并验证按亚组患者获得的模型,该模型根据经修订的《慢性阻塞性肺疾病全球倡议》( 2011年)和更新的西班牙指南(2014年)。此外,我们想确认,如果加重次数被两者之间的间隔所取代,则所有指标的预后能力都会提高,并评估对患者生活方式,社交网络和治疗依从性的影响。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号